ERBB2 and breast carcinoma: CDK4/6 inhibitors (CDK4/6i), such as Palbociclib, Ribociclib and Abemaciclib, have recently gained FDA-approval and shown success in the treatment of advanced metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer [15].